Shopping Cart
- Remove All
Your shopping cart is currently empty
Emactuzumab
🥰Excellent
Catalog No. T76776Cas No. 1448221-67-7
Alias RO 5509554, RG 7155
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).
Emactuzumab
🥰Excellent
Purity: 97.3% (SEC-HPLC)
Catalog No. T76776Alias RO 5509554, RG 7155Cas No. 1448221-67-7
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $328 | In Stock | |
| 5 mg | $747 | In Stock | |
| 10 mg | $1,160 | In Stock | |
| 25 mg | $1,720 | In Stock | |
| 50 mg | $2,290 | In Stock | |
| 100 mg | $3,120 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Emactuzumab"
Gilteritinib
Cited
ASP2215
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
- $34
Size
QTY
CitedPexidartinib
Cited
PLX-3397
T21151029044-16-3
Pexidartinib (PLX-3397) is a capsule containing a small-molecule receptor tyrosine kinase (RTK) inhibitor targeting KIT, CSF1R, and FLT3, with potential antineoplastic activity.
- $40
Size
QTY
CitedPLX5622 Cited
PLX-5622
T71001303420-67-8
PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor.
- $97
Size
QTY
CitedCabozantinib S-malate
XL184, Cabozantinib Malate, Cabozantinib
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
- $40
Size
QTY
Masitinib
AB1010
T2609790299-79-5
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- $31
Size
QTY
Sotuletinib Cited
BLZ945
T6119953769-46-5
Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor (IC50: 1 nM), >1000-fold selective against its closest receptor tyrosine kinase homologs.
- $31
Size
QTY
CitedGW786034B
Votrient HCl, Pazopanib HCl, GW786034 HCl
T6930635702-64-6
Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
- $48
Size
QTY
UNC2025
UNC-2025, UNC 2025, mrx-6313
T70071429881-91-3
UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
- $33
Size
QTY
Sitravatinib Cited
MGCD516, MG516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
- $47
Size
QTY
CitedNCT-503 Cited
NCT 503
T42131916571-90-8
NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=2.5 µM) with no activity against other dehydrogenases. NCT-503 has antitumor activity and inhibits the growth of PHGDH-dependent tumors.
- $35
Size
QTY
CitedGW2580
SC-203877, GW 2580
T2659870483-87-7
GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
- $43
Size
QTY
Linifanib
RG3635, AL-39324, ABT-869
T2514796967-16-3
Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: 66 nM). Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).
- $43
Size
QTY
Select Batch
Concentration:3.74 mg/mL
Purity:97.3% (SEC-HPLC)
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT). |
| In vitro | RG7155 (30 μg/mL; 6 days) induces cell death of in vitro-differentiated human M2-like macrophages.[2] Inducing cell death, RG7155 (0-10 μg/mL; 7 days) inhibited the viability of CSF-1-differentiated macrophages with an IC50 of 0.3 nM.[2] Emactuzumab, with a high affinity binding to human and cynomolgus CSF-1R (Kd = 0.2 nM), effectively prevents CSF-1R dimerization.[2] |
| In vivo | Emactuzumab (0.1、1、10、30 and 100 mg/kg; i.v.; once; male cynomolgus monkey) increased CSF-1 concentration in serum.[2] RG7155 (0, 30, and 100 mg/kg; i.v.; once weekly; for 2 weeks; male and female cynomolgus) Efficiently reduced CSF-1R and CD68+163+ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.[2] |
| Alias | RO 5509554, RG 7155 |
| Molecular Weight | 144.4 kDa |
| Cas No. | 1448221-67-7 |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Emactuzumab | purchase Emactuzumab | Emactuzumab cost | order Emactuzumab | Emactuzumab chemical structure | Emactuzumab in vivo | Emactuzumab in vitro | Emactuzumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.